Cáncer de Mama Invasor Triple negativo, presentación y sobrevida a 5 años, en el Instituto Oncológico Nacional “Dr. Juan Tanca Marengo”Solca.

Introduction: Triple-negative Breast Cancer (TNBC) is characterized by the absence of immunohistochemical markers for estrogen receptors, progesterone and human epidermal growth factor receptor 2 (HER2). It is associated with aggressive clinical behavior and low survival. The aim of this report was to determine the survival in a group of patients with TNBC in a cancer center. Methods: The present retrospective study was carried out in the National Oncology Institute-SOLCA of Guayaquil, in the study period from January 2001 to December 2005. Women with TNBC were included. The variables described were demographic, recurrence patterns, survival, adjuvant, neoadjuvant and presence of Ki-67 marker. The statistical package used was SPSS 19.0 for PC. Results: Of 1153 records of patients with breast cancer, 250 cases (21.7%) corresponded to TNBC, with age 50 ± 3 years. Infiltrating ductal carcinoma occurred in 235 cases (94%), lobular carcinoma in 9 cases (3.6%), atypical spinal cord carcinoma in 5 patients (2.0%) and papillary carcinoma in 1 patient (0.4%). The overall survival was 38.05 months. For the group that abandoned the treatment, the survival was 14.57 months and for the group that did not abandon the treatment it was 61.54 months P <0.001. Of 200 patients who did not abandon treatment, 81 had recurrence (40.5 %), at 15.6 months. The most frequent sites of recurrence were: local 36 %, bone 28 %, lung 25 %, central nervous system 17 % and liver 11 %. Conclusions: In the present study the survival of the patients with TNBC was less than 15 months in the group that leaves the treatment and the overall survival was of 38.05 months.